1. Home
  2. SCTX vs SMTI Comparison

SCTX vs SMTI Comparison

Compare SCTX & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SCTX

Scribe Therapeutics Inc. Common Stock

N/A

Current Price

$31.70

Market Cap

330.1M

Sector

Health Care

ML Signal

N/A

Logo Sanara MedTech Inc.

SMTI

Sanara MedTech Inc.

HOLD

Current Price

$34.65

Market Cap

313.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCTX
SMTI
Founded
N/A
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
330.1M
313.5M
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
SCTX
SMTI
Price
$31.70
$34.65
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.00
AVG Volume (30 Days)
218.3K
471.8K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,586,976.00
Revenue This Year
N/A
$17.31
Revenue Next Year
N/A
$12.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.47
52 Week Low
$17.31
$16.05
52 Week High
$39.60
$35.70

Technical Indicators

Market Signals
Indicator
SCTX
SMTI
Relative Strength Index (RSI) 62.83 78.70
Support Level $19.09 $33.99
Resistance Level $39.60 N/A
Average True Range (ATR) 4.12 0.25
MACD 1.05 -0.32
Stochastic Oscillator 66.75 78.57

Price Performance

Historical Comparison
SCTX
SMTI

About SCTX Scribe Therapeutics Inc. Common Stock

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

About SMTI Sanara MedTech Inc.

Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.

Share on Social Networks: